Apolipoprotein C-III (Apo-CIII)
ApoC-III is the OPPOSITE of ApoC-II — it INHIBITS LPL and BLOCKS triglyceride clearance. High ApoC-III → high triglycerides → prolonged atherogenic remnants → increased cardiovascular risk INDEPENDENT of LDL. The exciting news: new ApoC-III-lowering therapies (antisense/siRNA) can reduce ApoC-III by 70-90% and triglycerides by 50-80%. People with naturally low ApoC-III (genetic) have less heart disease — proving it’s a valid drug target.
Apolipoprotein C-III, or ApoC-III, is a small protein with a big impact on triglyceride metabolism — but unlike its cousin ApoC-II which activates triglyceride clearance, ApoC-III does the opposite. It INHIBITS lipoprotein lipase (LPL) and blocks the liver’s uptake of triglyceride-rich particles. In essence, ApoC-III keeps triglycerides elevated by preventing their removal from blood.
Why does this matter? High ApoC-III means slower triglyceride clearance and prolonged circulation of atherogenic remnant particles. This translates to increased cardiovascular risk independent of LDL cholesterol. Elevated ApoC-III is associated with heart attacks, strokes, and coronary artery disease — making it an emerging therapeutic target.
The exciting news: new medications that specifically lower ApoC-III (antisense oligonucleotides and siRNA therapies) have shown dramatic triglyceride reduction and cardiovascular benefits. ApoC-III has moved from a research curiosity to a genuine treatment target, making testing increasingly relevant.
Order Your Advanced Lipid Panel
Key Benefits of Testing
ApoC-III testing identifies elevated levels of this triglyceride-raising protein, providing insight beyond standard triglyceride measurement. High ApoC-III may explain why some patients have stubborn hypertriglyceridemia that doesn’t respond well to conventional treatments.
As ApoC-III-targeting therapies become available, testing identifies patients most likely to benefit from these new treatments — those with elevated ApoC-III driving their triglyceride elevation and cardiovascular risk.
What Does This Test Measure?
ApoC-III testing measures the concentration of apolipoprotein C-III protein in blood. This protein circulates on various lipoprotein particles, primarily VLDL, chylomicrons, and HDL.
How ApoC-III Raises Triglycerides
ApoC-III elevates triglycerides through multiple mechanisms:
Inhibits lipoprotein lipase (LPL):
- ApoC-III blocks LPL from breaking down triglycerides
- This is the OPPOSITE of ApoC-II’s activating effect
- Triglyceride-rich particles remain in circulation longer
Blocks hepatic uptake:
- ApoC-III prevents the liver from removing remnant particles
- Blocks receptors that normally clear these particles
- Remnants accumulate in blood
Increases VLDL secretion:
- ApoC-III promotes hepatic production of VLDL
- More triglyceride-rich particles enter circulation
ApoC-III and Cardiovascular Risk
Elevated ApoC-III increases cardiovascular risk through:
- Prolonged circulation of atherogenic remnant particles
- Pro-inflammatory effects on blood vessel walls
- Promotion of atherosclerosis independent of LDL
Genetic studies confirm causation: people with naturally low ApoC-III (loss-of-function mutations) have lower triglycerides AND reduced cardiovascular events.
ApoC-II vs. ApoC-III — Opposite Effects
ApoC-II: ACTIVATES LPL → Promotes triglyceride clearance → Deficiency causes high TG
ApoC-III: INHIBITS LPL → Blocks triglyceride clearance → Excess causes high TG
They are functional opposites in triglyceride metabolism.
Why This Test Matters
Independent Cardiovascular Risk Factor
Elevated ApoC-III predicts cardiovascular events independent of LDL cholesterol and standard lipid measures. It captures risk from triglyceride-rich particles and their remnants — a cardiovascular danger zone that LDL alone doesn’t fully reflect.
Explains Residual Risk
Patients on statin therapy with controlled LDL still have cardiovascular events. Elevated ApoC-III may explain part of this “residual risk” — their triglyceride metabolism and remnant particles remain problematic.
Therapeutic Target Identification
New ApoC-III-lowering therapies (volanesorsen, olezarsen) dramatically reduce triglycerides. Knowing ApoC-III levels identifies patients most likely to benefit from these emerging treatments.
Evaluates Hypertriglyceridemia Mechanism
High ApoC-III helps explain WHY triglycerides are elevated. This mechanistic insight guides treatment selection and predicts response.
Genetic Risk Assessment
ApoC-III levels are partly genetically determined. High levels may indicate genetic variants affecting APOC3 gene expression, relevant for family risk assessment.
What Can Affect Your ApoC-III?
Causes of High ApoC-III
Genetic factors:
- Genetic variants increasing APOC3 expression
- Strong familial patterns
- Part of familial hypertriglyceridemia syndromes
Metabolic conditions:
- Type 2 diabetes and insulin resistance — ApoC-III is regulated by insulin
- Metabolic syndrome
- Obesity
- Non-alcoholic fatty liver disease
Dietary factors:
- High carbohydrate intake, especially refined carbs and sugars
- Excess alcohol
- High fructose consumption
Other conditions:
Causes of Low ApoC-III (Generally Favorable)
Genetic factors:
- Loss-of-function mutations in APOC3 gene
- These individuals have naturally low triglycerides and reduced cardiovascular risk
- This genetic observation led to ApoC-III as a drug target
Medications (therapeutic reduction):
- ApoC-III antisense oligonucleotides (volanesorsen)
- ApoC-III siRNA therapies (olezarsen)
- These can reduce ApoC-III by 70-90%
Lifestyle factors (modest effects):
- Weight loss
- Reduced carbohydrate intake
- Exercise
- Fish oil/omega-3s (modest ApoC-III reduction)
Testing Considerations
Fasting recommended: For consistency, fasting testing is typically recommended.
Not widely available: ApoC-III is a specialized test not included in standard lipid panels. Requires specific ordering.
Correlation with triglycerides: ApoC-III generally correlates with triglycerides but provides additional mechanistic information.
When Should You Get Tested?
Severe or Refractory Hypertriglyceridemia
When triglycerides remain elevated despite standard treatments (lifestyle, fibrates, omega-3s), ApoC-III testing helps characterize the underlying mechanism.
Considering ApoC-III-Targeting Therapy
As new ApoC-III-lowering drugs become available, baseline testing identifies candidates and enables monitoring of treatment response.
Familial Chylomicronemia Syndrome Workup
In severe genetic hypertriglyceridemia, ApoC-III is part of comprehensive evaluation along with LPL activity, ApoC-II, and ApoA-V.
Cardiovascular Risk Assessment
In patients with residual cardiovascular risk despite controlled LDL, elevated ApoC-III may identify a treatable contributor.
Research and Advanced Lipid Profiling
For comprehensive understanding of triglyceride metabolism and cardiovascular risk.
Understanding Your Results
ApoC-III interpretation focuses on its contribution to triglyceride elevation and cardiovascular risk:
ApoC-III Levels
Lower ApoC-III: Favorable. Associated with efficient triglyceride clearance, lower triglyceride levels, and reduced cardiovascular risk. People with genetically low ApoC-III are protected from heart disease.
Normal ApoC-III: Typical triglyceride metabolism. Standard cardiovascular risk from this pathway.
Elevated ApoC-III: Impaired triglyceride clearance. Associated with higher triglycerides, prolonged remnant particle circulation, and increased cardiovascular risk. May be a target for intervention.
Markedly elevated ApoC-III: Significant contributor to hypertriglyceridemia. Strong candidate for ApoC-III-lowering therapies when available.
Relationship with Triglycerides
ApoC-III and triglycerides generally correlate, but the relationship provides additional information:
- High TG with high ApoC-III: ApoC-III is likely a significant driver; may respond well to ApoC-III-lowering therapy
- High TG with normal ApoC-III: Other mechanisms may be more important (LPL deficiency, ApoC-II deficiency, etc.)
Genetic Implications
Very high or very low ApoC-III may indicate genetic variants. Family testing may be appropriate.
What to Do About Abnormal Results
For Elevated ApoC-III
Lifestyle modifications:
- Reduce refined carbohydrates and sugars: These increase hepatic ApoC-III production
- Limit alcohol: Alcohol raises triglycerides and may increase ApoC-III
- Lose weight: Obesity is associated with higher ApoC-III
- Exercise regularly: Improves triglyceride metabolism
- Omega-3 fatty acids: Modestly reduce ApoC-III
Optimize metabolic health:
- Control diabetes — insulin regulates ApoC-III
- Address insulin resistance
- Treat metabolic syndrome components
Standard triglyceride-lowering medications:
- Fibrates: Reduce ApoC-III somewhat in addition to lowering triglycerides
- High-dose omega-3s: Modest ApoC-III reduction
- Statins: May slightly reduce ApoC-III
ApoC-III-specific therapies (emerging):
- Volanesorsen: Antisense oligonucleotide reducing ApoC-III production by ~70-80%
- Olezarsen: siRNA therapy with similar dramatic ApoC-III reduction
- These can reduce triglycerides by 50-80%
- Currently for severe hypertriglyceridemia; indications may expand
Monitor Response
Recheck ApoC-III and triglycerides after intervention to assess response and guide further treatment.
Related Health Conditions
Hypertriglyceridemia
Central Role: Elevated ApoC-III is a major driver of hypertriglyceridemia. It explains why triglycerides are elevated and represents a therapeutic target.
Cardiovascular Disease
Independent Risk Factor: High ApoC-III increases heart attack and stroke risk independent of LDL. It promotes atherogenic remnant particles and vascular inflammation.
Type 2 Diabetes
Bidirectional Relationship: Diabetes increases ApoC-III (insulin normally suppresses it), and high ApoC-III worsens diabetic dyslipidemia.
Metabolic Syndrome
Part of the Pattern: Elevated ApoC-III accompanies the high triglycerides and insulin resistance characteristic of metabolic syndrome.
Familial Chylomicronemia Syndrome
Part of Evaluation: Some cases of severe genetic hypertriglyceridemia involve elevated ApoC-III as a contributing factor.
Why Testing Matters
ApoC-III has emerged from a research biomarker to a therapeutic target. Testing identifies elevated levels that contribute to hypertriglyceridemia and cardiovascular risk. As specific ApoC-III-lowering therapies become available, knowing your ApoC-III level becomes clinically actionable — it identifies who will benefit most from these transformative new treatments.
Related Biomarkers Often Tested Together
Triglycerides — The clinical manifestation of ApoC-III’s effects. Essential companion test.
Apolipoprotein C-II — The LPL activator (opposite of ApoC-III). Complete picture of LPL regulation.
Apolipoprotein B — Measures atherogenic particles including triglyceride-rich remnants.
LDL Cholesterol — Standard lipid measure. ApoC-III captures risk beyond LDL.
Remnant Cholesterol — Directly measures the atherogenic particles that ApoC-III increases.
hs-CRP — Inflammation marker. ApoC-III has pro-inflammatory effects.
Note: Information provided in this article is for educational purposes and doesn’t replace personalized medical advice.
Frequently Asked Questions
Apolipoprotein C-III (ApoC-III) is a protein that inhibits triglyceride clearance from blood. It blocks lipoprotein lipase (the enzyme that breaks down triglycerides) and prevents the liver from removing triglyceride-rich particles. High ApoC-III means higher triglycerides.
They have OPPOSITE effects. ApoC-II activates lipoprotein lipase (promotes triglyceride clearance). ApoC-III inhibits lipoprotein lipase (blocks triglyceride clearance). ApoC-II deficiency and ApoC-III excess both lead to high triglycerides.
Elevated ApoC-III keeps atherogenic triglyceride-rich particles and their remnants circulating longer. These particles penetrate artery walls and promote atherosclerosis. ApoC-III also has direct pro-inflammatory effects. High ApoC-III predicts heart attacks independent of LDL.
Lifestyle changes (reducing refined carbs, losing weight, exercising, limiting alcohol) modestly reduce ApoC-III. Fibrates and omega-3s have some effect. New drugs specifically targeting ApoC-III (volanesorsen, olezarsen) can reduce it by 70-90%.
Volanesorsen is approved in some regions for familial chylomicronemia syndrome. Other ApoC-III-targeting therapies are in late-stage development. These drugs dramatically lower triglycerides and may reduce cardiovascular risk.
No — ApoC-III is a specialized test not included in standard lipid panels. It’s most useful for severe hypertriglyceridemia, treatment-resistant cases, or when considering ApoC-III-targeted therapy.
Fasting is typically recommended for consistency, similar to triglyceride testing.
No — low ApoC-III is beneficial. People with naturally low ApoC-III (from genetic variants) have lower triglycerides and reduced cardiovascular disease. This genetic observation made ApoC-III an attractive drug target.
References
Key Sources:
- Taskinen MR, Packard CJ, Borén J. Emerging evidence that ApoC-III inhibitors provide novel options to reduce the residual CVD. Curr Atheroscler Rep. 2019;21(8):27.
- Gaudet D, et al. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med. 2015;373(5):438-447.
- TG and HDL Working Group. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371(1):22-31.
